Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RuiYi Signs On New Partners To Develop Anti-IL6 mAb In China

This article was originally published in PharmAsia News

Executive Summary

The China-U.S. hybrid signs on Shanghai-based Genor Biopharma in a co-development deal and contract manufacturer CMC Biologics to develop a cell line for RYI-008 for global manufacturing.

You may also be interested in...



arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic

European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Topics

Related Companies

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel